Proteolysis: A Biological Process Adapted in Drug Delivery, Therapy, and Imaging
- 9 March 2009
- journal article
- review article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 20 (9) , 1683-1695
- https://doi.org/10.1021/bc800500a
Abstract
In many diseases, protease expressions are found deregulated when compared with them at the healthy states. The unique ability to hydrolyze protein amide bonds has made those deregulated proteases attractive biological triggers in drug development. Proteolysis has been widely applied in pro-drug design to achieve favorable pharmacokinetics. Controlled drug delivery systems are also reported by incorporating protease-sensitive motifs onto bio-, inorganic-, or organic- materials. In addition, protease responsive molecular probes are developed for in vitro bioanalysis and in vivo diagnostic imaging. This review focuses on various proteolysis-dependent approaches to drug delivery, therapy, and imaging. References are selected to illustrate the concepts and demonstrate the potentials of these enzyme-responsive strategies.Keywords
This publication has 136 references indexed in Scilit:
- Tumour endoproteases: the cutting edge of cancer drug delivery?British Journal of Pharmacology, 2008
- Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancerBioorganic & Medicinal Chemistry, 2008
- Protease-Sensitive Fluorescent NanofibersBioconjugate Chemistry, 2007
- Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activationProceedings of the National Academy of Sciences, 2007
- Selective Fluorescence Probes for Dipeptidyl Peptidase ActivityFibroblast Activation Protein and Dipeptidyl Peptidase IVBioconjugate Chemistry, 2007
- Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicinEuropean Journal Of Cancer, 2006
- Protease-Modulated Cellular Uptake of Quantum DotsNano Letters, 2006
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006
- Superior therapeutic efficacy of N-l-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drugEuropean Journal Of Cancer, 1999